非布司他用药量多少？

In February 2009, the U.S. Food and Drug Administration (FDA) approved the long-term treatment of patients with gout and hyperuricemia. What is the dosage of nafebuxostat?

How to take febuxostat: Start with febuxostat at 10 mg/day for 2 weeks, then increase to 20 mg/day for 4 weeks, and then increase to 40 mg/day. Starting with a low dose and gradually increasing the dose can prevent acute gout attacks caused by initial changes in blood uric acid levels. Treat with febuxostat 40 mg/day for 6 months, and check the uric acid level regularly. Generally, it takes 6 months to clean up excess blood uric acid in the body. 

After 6 months of treatment:

(1) If the serum uric acid level remains between 240 umol/l and 360 umol/l, maintain febuxostat 40 mg/day treatment.

  (2) If the blood uric acid level is higher than 360 umol/l, increase the dose of fexostatin by 60 mg/day, up to a maximum of 80 mg/day, and monitor blood uric acid, liver and kidney function regularly. 

If the serum uric acid level is less than 240 umol/l, the dose of febuxostat can be reduced to 20 mg/day and the treatment can be maintained for 6 months.

We need to remind everyone that febuxostat can control gout but cannot cure gout. Uric acid-lowering treatment for gout patients is a long-term process. Once the blood uric acid reaches the target, the drug cannot be stopped at will. The drug must be reduced or stopped according to the doctor's advice based on the uric acid level.

Unauthorized discontinuation of uric acid-lowering drugs can easily cause blood uric acid to return to the pre-treatment level, which can not only cause another gout attack, but long-term failure of blood uric acid to reach the standard will also bring the risk of kidney, cardiovascular and cerebrovascular damage.

It can reduce uric acid levels in the blood of patients with hyperuricemic gout. Clinical studies have shown that febuxostat is safe and effective. Febuxostat is metabolized by the liver and does not rely on renal excretion. Therefore, there is no need to reduce the dose for patients with moderate to severe hepatic and renal insufficiency.

Recommended related hot articles: /newsDetail/74676.html